BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharmaceuticals (PCRX) PT Lifted to $136 at Piper Jaffray
February 25, 2015 9:49 AM ESTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and bumped his price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $136.00 (from $134.00) following Q4 results yesterday.
Amsellem commented, "This morning, Pacira reported non-GAAP diluted EPS of $0.35, ahead of the Street estimate of $0.25, on Exparel sales of... More
Pacira Pharmaceuticals (PCRX) PT Lifted to $133 at Wedbush
February 25, 2015 6:57 AM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $133.00 (from $130.00) after preannounced Q4 EXPAREL sales and Q4 was 1st profitable quarter on GAAP basis.
Moussatos believe that the Street has overlooked the impact of EXPAREL's... More
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
February 24, 2015 6:31 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.35, $0.08 better than the analyst estimate of $0.27. Revenue for the quarter came in at $61.8 million versus the consensus estimate of $62.1 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More